8-K
filed May 9, 2024, 7:59 PM ET
ticker GH
CIK 0001576280
earnings
confidence high
sentiment positive
materiality 0.75
Guardant Health Q1 revenue up 31% to $168.5M; raises 2024 revenue guidance to $675-685M
Guardant Health, Inc.
2024-Q1 EPS reported
-$0.94
revenue$168,491,000
- Revenue $168.5M (+31% YoY); net loss narrowed to $115M ($0.94 loss per share) from $133.5M.
- Precision oncology revenue $156.2M (+38%); clinical tests +20%, biopharma tests +37%.
- 2024 revenue guidance raised to $675-685M (prior $655-670M); FCF guidance improved to $(275)-$(285)M.
- Non-GAAP gross margin ex-screening guided to 61%-63% (prior 60%-62%).
- ECLIPSE published in NEJM; FDA Advisory Committee on May 23; Shield IVD launch expected post-approval.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Guardant Health, Inc. reported full year 2024 results: revenue $675 to $685 million. Guidance raised.
- Period
- full year 2024
- Revenue
- $675 to $685 million
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
Guardant Health now expects full year 2024 revenue excluding screening to be in the range of $675 to $685 million, representing growth of 20% to 21% compared to full year 2023
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Guardant Health, Inc. reported the quarter ended March 31, 2024 results: revenue $168.5 million, net income $115.0 million, EPS $0.94.
- Period
- the quarter ended March 31, 2024
- Revenue
- $168.5 million
- Net income
- $115.0 million
- EPS
- $0.94
- Result
- reported results
Exact text from the filing
Revenue was $168.5 million for the first quarter of 2024, a 31% increase from $128.7 million for the corresponding prior year period.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.